SCHEMBL3799558

SCHEMBL3799558

COc1ccc(CNc2c(C(=O)O)ccnc2Cl)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ASPH Q12797 4/20 0.76
KDM8 Q8N371 4/20 0.76
KDM4E B2RXH2 3/20 0.76
RIOX2 Q8IUF8 1/20 0.54
KDM5A P29375 1/20 0.49
KDM5B Q9UGL1 1/20 0.49
VNN1 O95497 3/20 0.48
CLK4 Q9HAZ1 3/20 0.46
CLK1 P49759 1/20 0.46
CLK2 P49760 1/20 0.46
DYRK1A Q13627 1/20 0.46
DYRK1B Q9Y463 1/20 0.46
FFAR1 O14842 1/20 0.45
KDM4C Q9H3R0 2/20 0.45
HIF1A Q16665 1/20 0.44
LMNA P02545 1/20 0.44
PPARA Q07869 1/20 0.44
ADORA3 P0DMS8 1/20 0.43
ADORA2A P29274 1/20 0.43
ADORA1 P30542 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4901416 0.79 CLK4 (0.50) ASPHKDM8KDM4EVNN1CLK4
SCHEMBL4855920 0.74 KDM4C (0.76) ASPHKDM8KDM4ERIOX2KDM5A
SCHEMBL1715769 0.74 NPC1 (0.66) ASPHKDM8KDM4ERIOX2KDM5B
SCHEMBL24157190 0.74 KDM4E (0.65) ASPHKDM8KDM4ERIOX2VNN1
SCHEMBL7823324 0.74 MCHR1 (0.61) ASPHKDM8KDM4ERIOX2VNN1
SCHEMBL30253210 0.74 KDM4E (0.65) ASPHKDM8KDM4ERIOX2VNN1
SCHEMBL3730790 0.74 KDM4E (0.76) ASPHKDM8KDM4ERIOX2VNN1
SCHEMBL6103515 0.73 KDM4E (0.53) ASPHKDM8KDM4ERIOX2KDM5B
SCHEMBL31139804 0.73 KDM4E (0.53) ASPHKDM8KDM4ERIOX2KDM5B
SCHEMBL24987203 0.73 KDM4E (0.50) ASPHKDM8KDM4ERIOX2VNN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825132-B2 Inhibition of FGFR3 and treatment of multiple myeloma NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-11-02 US disclosed
US-20050261307-A1 Inhibition of FGFR3 and treatment of multiple myeloma CHIRON CORPORATION 2005-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261307-A1 Inhibition of FGFR3 and treatment of multiple myeloma FGFR3, FGFR1, FGFR2 ASPH 1666/4885KDM8 1560/4885KDM4E 3240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.